Extract

1) To evaluate the efficacy of MK-0822 5 mg once daily relative to placebo in the prevention of knee cartilage loss over 12 months of treatment based on MRI assessments of cartilage normalized volume in the medial tibial region of the knee. 2) To investigate the overall safety and tolerability of MK-0822 in OA patients over a treatment period of 12 months.

Inclusion criteria

• Osteoarthritis

Links

• ictrp
• euctr